These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2523870)

  • 1. Acute and chronic effects of ramipril and captopril in congestive heart failure.
    de Graeff PA; Kingma JH; Viersma JW; Wesseling H; Lie KI
    Int J Cardiol; 1989 Apr; 23(1):59-67. PubMed ID: 2523870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.
    de Graeff PA; Kingma JH; Dunselman PH; Wesseling H; Lie KI
    Am J Cardiol; 1987 Apr; 59(10):164D-170D. PubMed ID: 3034026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.
    Manthey J; Osterziel KJ; Röhrig N; Dietz R; Hackenthal E; Schmidt-Gayk H; Kübler W
    Am J Cardiol; 1987 Apr; 59(10):171D-175D. PubMed ID: 2953224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global and regional hemodynamic effects of ramipril in congestive heart failure.
    Crozier IG; Ikram H; Nicholls MG; Jans S
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):688-93. PubMed ID: 2481181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.
    Todd PA; Benfield P
    Drugs; 1990 Jan; 39(1):110-35. PubMed ID: 2138076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
    Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.
    Crozier IG; Ikram H; Nicholls MG; Jans S
    Am J Cardiol; 1987 Apr; 59(10):155D-163D. PubMed ID: 3034025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.
    Vogt A; Unterberg C; Kreuzer H
    Am J Cardiol; 1987 Apr; 59(10):149D-154D. PubMed ID: 3034024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
    Vasmant D; Bender N
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state kinetics of ramipril in renal failure.
    Schunkert H; Kindler J; Gassmann M; Lahn W; Irmisch R; Debusmann ER; Ocón-Pujadas J; Sieberth HG
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S52-4. PubMed ID: 2474104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
    Iimura O; Shimamoto K
    Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
    Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramipril: a review of the new ACE inhibitor.
    Mills TP
    J Ark Med Soc; 1992 Feb; 88(9):437-40. PubMed ID: 1532570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of ramipril.
    Ball SG; Robertson JI
    Am J Cardiol; 1987 Apr; 59(10):23D-27D. PubMed ID: 3034028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril: review of pharmacology.
    Becker RA; Schölkens B
    Am J Cardiol; 1987 Apr; 59(10):3D-11D. PubMed ID: 3034030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
    Bauer B; Lorenz H; Zahlten R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
    Witte PU; Walter U
    Am J Cardiol; 1987 Apr; 59(10):115D-120D. PubMed ID: 3034018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of captopril and enalapril in patients with severe chronic heart failure.
    Packer M; Lee WH; Yushak M; Medina N
    N Engl J Med; 1986 Oct; 315(14):847-53. PubMed ID: 3018566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.